DAWEX
26.3.2020 22:54:08 CET | Business Wire | Press release
Under the impulsion of the World Health Organization and the European Union stressing the importance of data sharing, Dawex , the leading data exchange technology company, today announced launching a COVID-19 Data Exchange initiative. The platform will be available pro bono to a large community of companies and organizations looking to contribute to the resolution of this crisis. The technology enables the exchange of vital non-personal data to hinder COVID-19’s dissemination and restrain its economic impact.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200326005767/en/
Scientific communities, hospitals and healthcare operations, pharmaceutical organizations, retailers, transport & logistics companies, specialized equipment manufacturers and distributors, consulting organizations, technology companies and health tech startups, banks, insurance, global and regional health organizations, governmental agencies, municipalities and other public services will be able to securely and easily access, publish, and exchange multiple sources of non-personal data worldwide, therefore acquiring more capabilities to answer crisis-related complex questions, faster.
“There is an unparalleled demonstration of solidarity from many organizations to contribute to the resolution of this crisis. It was an evidence for Dawex to immediately engage its resources and technology to bring the best environment to all these organizations to exchange data in the best conditions,” says Laurent Lafaye, co-founder and co-CEO of Dawex.
Join worldwide and regional organizations in this endeavour and proactively exchange critical non-personal data to contribute to stopping the virus’ progression and its economic impact. Get involved now |
By using COVID-19 Data Exchange, participants remain in full control of the data they share, decide with whom they share it, and keep track of all data flows. Only vetted participants from public and private organizations will be granted access to the COVID-19 Data Exchange to ensure confidentiality and relevance of the data exchanges.
“COVID-19 crisis is challenging the way we will use data in the future. Thousands of data providers are willing to share their sources of data, right now, for free. Without trust, fairness and use cases, this effort will be pointless. Our dedicated team of experts from Deloitte, in data management, healthcare and artificial intelligence will make the most out of this coalition and Dawex technology,” says Mathieu Colas, Senior Partner at Deloitte.
“The COVID-19 Data Exchange will facilitate and accelerate data exchanges while we are in the midst of the storm. Moreover, it brings the community together, strengthening our ability to respond to future crises and prepare for a better and stronger future,” says Fabrice Tocco, co-founder and co-CEO of Dawex.
About Dawex
Dawex, a leading data exchange technology company, allows organizations to orchestrate data circulation by sourcing and exchanging data directly, securely and in full compliance with regulations. Today 10,000 organizations from 20+ sectors rely on Dawex Data Exchange solutions to build their data exchange strategy. Created in 2015, Dawex is an international company headquartered in France, and serving customers in more than 50 countries. www.dawex.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005767/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom